In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars CommitteeJune 13 2017 - IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee. Ingrid has played a leading role in the establishment of… Read More
European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the WorldMarch 14, 2017 - On 9th March, IFPMA launched jointly with EFPIA and EBE a position paper entitled Considerations for physicians on switching decisions regarding biosimilars. Physician-led switching of biological medicines is a well-known medical practice. Although data on the frequency… Read More
IGBA Statement on the Final Report of the United Nations Secretary General’s High Level Panel on Access to MedicinesNovember 15, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) believes that generic and biosimilar medicines can play a fundamental role in improving access to high quality medicines for patients worldwide. Read More